Pad Chivukula, CSO and COO, will provide a brief over view of company technology. Key Opinion Leader Annette Feigenbaum, MBChB, FRCP, DABMG (UC San Diego) discusses Ornithine transcarbamylase (OTC) deficiency.
Dec 11, 2018 at 2:00 PM EST
The call will feature a presentation by key opinion leader Annette Feigenbaum, MBChB, FRCP, DABMG (UC San Diego), who will discuss the disease pathogenesis, manifestation, natural history and current treatment options for Ornithine transcarbamylase (OTC) deficiency. Dr. Feigenbaum will be available to answer questions at the conclusion of the call.
Dr. Pad Chivukula, Chief Scientific Officer of Arcturus Therapeutics, will also provide a brief overview of the company's LUNAR-OTC program, which utilizes the company's proprietary LUNAR® delivery platform to safely and effectively deliver OTC mRNA to liver cells, resulting in restoration of disease markers to normal levels.